Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase expressed at early stages of normal development and in various cancers including ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), in which it is the main therapeutic target. ALK tyrosine kinase inhibitors (ALK TKIs) have greatly...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuan, He, Jing, Xu, Manyu, Xue, Qingfeng, Zhu, Cindy, Liu, Juan, Zhang, Yaping, Shi, Wenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862178/
https://www.ncbi.nlm.nih.gov/pubmed/35211406
http://dx.doi.org/10.3389/fonc.2022.815654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862178/
https://www.ncbi.nlm.nih.gov/pubmed/35211406
http://dx.doi.org/10.3389/fonc.2022.815654

Ejemplares similares